← Back to Clinical Trials
Recruiting NCT06494033

NCT06494033 Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06494033
Status Recruiting
Phase
Sponsor University of Miami
Condition Lung Diseases
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2024-07-03
Primary Completion 2026-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2024-07-03 with a primary completion date of 2026-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.

Eligibility Criteria

Inclusion Criteria: 1. Adult patients over 18 years of age 2. Lung transplant candidates with positive CMV IgG 3. Anticipated to receive a lung transplant (both double lung and single lung) Exclusion Criteria: 1. Negative CMV IgG prior transplant 2. Pregnant or breastfeeding women 3. HIV infected patients 4. Combined organ (e.g., lung-heart, lung-kidney) transplant candidates

Contact & Investigator

Central Contact

Yoichiro Natori, MD

✉ yxn138@med.miami.edu

📞 3053556323

Principal Investigator

Yoichiro Natori, MD

PRINCIPAL INVESTIGATOR

University of Miami

Frequently Asked Questions

Who can join the NCT06494033 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Lung Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06494033 currently recruiting?

Yes, NCT06494033 is actively recruiting participants. Contact the research team at yxn138@med.miami.edu for enrollment information.

Where is the NCT06494033 trial being conducted?

This trial is being conducted at Miami, United States.

Who is sponsoring the NCT06494033 clinical trial?

NCT06494033 is sponsored by University of Miami. The principal investigator is Yoichiro Natori, MD at University of Miami. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology